Panelists discuss how evaluating the efficacy of treatment in chronic inflammatory demyelinating polyneuropathy (CIDP) involves a combination of clinical, functional, and electrophysiological measures, and emphasize the importance of individualizing treatment approaches based on disease subtype, prior therapy response, comorbidities, patient preferences, and ongoing monitoring to optimize patient outcomes.
The research portfolio director at the Muscular Dystrophy Association discussed the evolving ALS therapeutic landscape, highlighting advances in genetic and RNA-based interventions. [WATCH TIME: 6 minutes]
An expert discusses the critical role of dystrophin in maintaining muscle integrity across multiple systems, explaining how its absence in Duchenne and Becker muscular dystrophy leads to widespread complications—including neurologic, pulmonary, cardiac, gastrointestinal, urinary, and orthopedic issues—driven by chronic muscle damage, inflammation, and fibrosis.
An expert discusses the evolving treatment landscape of Duchenne muscular dystrophy (DMD), highlighting advances in gene therapy, exon-skipping agents, and novel corticosteroids that aim to slow disease progression, improve muscle function, and enhance quality of life, while emphasizing the growing role of personalized medicine and early intervention in optimizing long-term outcomes.
Panelists discuss how the recently FDA-approved SPN-830 apomorphine infusion pump demonstrated significant efficacy in reducing off time and improving motor function in the INFUS-ON study, with physicians expressing optimistic views about both the US and European clinical trial results.
Panelists discuss how continuous subcutaneous apomorphine infusion (CSAI) demonstrates favorable pharmacokinetics compared with other formulations, with the TOLEDO study and its extension showing significant reductions in off time and improvements in motor function with manageable safety profiles.
The chief scientific officer at Quanterix gave a clinical overview on how the company’s Simoa platform enables ultrasensitive detection of neurodegeneration biomarkers in blood, transforming Alzheimer and Parkinson disease research. [WATCH TIME: 3 minutes]
The chief executive officer and founder at CureDuchenne shared her emotional journey from her son’s diagnosis of Duchenne to embracing a new path focused on advocacy, adaptation, and resilience. [WATCH TIME: 4 minutes]
Experts discussed how aging impacts multiple sclerosis management, treatment decisions, and overall patient health. [WATCH TIME: 5 minutes]
This closing episode looks ahead to the future of SMA care, examining how updated best practices aim to accelerate access, optimize outcomes, and fuel ongoing progress.
Experts discussed the current and future applications of AI and machine learning in multiple sclerosis research and clinical care, highlighting both opportunities and limitations. [WATCH TIME: 9 minutes]
Panelists discuss how early recognition of dyskinesia symptoms, ongoing patient-clinician communication, and individualized treatment strategies are key to effectively managing Parkinson disease and improving patients’ quality of life.
Panelists discuss how long-term data from the Clarity AD OLE study support lecanemab as an effective maintenance therapy for early Alzheimer disease, with reduced infusion frequency improving patient and caregiver quality of life, while potentially delaying disease progression and enhancing long-term cognitive and functional outcomes.
Experts discussed the promise and uncertainty surrounding BTK inhibitors and CAR T-cell therapy in addressing progressive multiple sclerosis. [WATCH TIME: 8 minutes]
Panelists discuss how interim results from the Clarity AD open-label extension demonstrate that lecanemab provides sustained cognitive and functional benefits with a stable safety profile over time, reinforcing the value of early initiation and continuous treatment in Alzheimer disease management.
This episode tackles how proactive, interdisciplinary care and dedicated coordination models are transforming the delivery of SMA treatment across clinical settings.
Panelists comment on how treatment decisions for adolescents and adults with SMA are shaped by lifestyle, quality of life, logistical realities, and access to care.
Neurology News Network. for the week ending May 10, 2025. [WATCH TIME: 4 minutes]
A duo of experts from Feinberg School of Medicine discussed the growing role of clinical algorithms, risk stratification, and treatment considerations in managing paraneoplastic neurologic syndromes alongside cancer therapies. [WATCH TIME: 4 minutes]
Panelists discuss how patients have experienced continuous subcutaneous infusion therapy from the perspective of medical professionals.
The clinical associate professor of neurology and neurosurgery at NYU Langone talked about the promise of machine learning in identifying patients at high risk for hematoma expansion to guide care. [WATCH TIME: 2 minutes]
Panelists discuss how phase 3 clinical trials demonstrated the efficacy, safety, and quality of life improvements associated with continuous subcutaneous foscarbidopa/foslevodopa in both short-term and long-term studies.
A panelist discusses how selecting the optimal benzodiazepine rescue medication depends on factors such as route of administration, setting, and patient preference, with intranasal formulations increasingly favored for their rapid onset, ease of use, and greater acceptance in outpatient and home environments.
The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the evolving role of noninvasive neuromodulation in promoting brain plasticity. [WATCH TIME: 3 minutes]
This episode explores treatment considerations for patients already living with SMA, emphasizing individualized goals, medical complexity, and the value of subtle clinical improvements.
Panelists discuss how clinical experience with efgartigimod, a newly FDA-approved treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), demonstrates positive outcomes and a favorable safety profile, while also addressing challenges in transitioning patients from other therapies and emphasizing the importance of proper patient selection and monitoring.
Panelists discuss how a recent study highlights concerns about transitioning patients with chronic inflammatory demyelinating polyneuropathy (CIDP) from intravenous immunoglobulin (IVIg) to efgartigimod, emphasizing the need for a cautious, gradual approach, careful patient selection, and close monitoring to address issues like symptom exacerbation, delayed response, and safety risks.
The clinical professor of stroke neurology and neurocritical care at Stanford University discussed the shifting perspective on early blood pressure lowering in intracerebral hemorrhage. [WATCH TIME: 4 minutes]
In this episode, neurologists unpack the urgent and complex treatment decisions in newly diagnosed SMA, highlighting clinical factors, family input, and the importance of shared decision-making.
Panelists discuss how adjunctive therapies play a crucial role in managing Parkinson disease symptoms, with a particular focus on apomorphine’s unique position in the treatment landscape due to its distinct dopamine receptor binding profile compared with other dopaminergic agents.
